Navigation Links
Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C
Date:8/19/2009

ithout ribavirin, include hearing impairment, hearing loss, serious skin reactions, including erythema multiforme major, and infections (bacterial, viral and fungal).

Full prescribing information is available at www.rocheusa.com.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the completed Phase 3 CAPACITY program, now in pre-registration, which evaluated pirfenidone for the treatment of patients with IPF; RECAP, an open-label extension study from CAPACITY and a research program focused on small molecules for the treatment of pulmonary disease. The hepatology portfolio includes the HCV pr
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Rochester Medical Reports Third Quarter Results
2. Roche Cardiac 200 Offers Rapid Cardiac Diagnostics for the Point of Care
3. Rochester Medical Announces Third Quarter 2009 Earnings Conference Call July 30, 2009
4. Enigma Diagnostics Announces Signing of Patent Licenses With Roche Molecular Systems, Inc.
5. Roche Diabetes Care Announces Unique Coaching Program for Diabetes Educators as Part of Long-Term Commitment to Fight the Disease
6. NJLRA Statement in Response to Roches Discontinuation of Accutane(R)
7. Orochem Technologies Acquires Oligonet, a Custom Oligo Synthesis Business
8. Purple Communications Dream Bigger Initiative Honors Rochester Physician and Deaf Community Trailblazer
9. Rochester Medical Corporation Set to Join Russell 3000 Index
10. Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack
11. Raptor Pharmaceuticals to Collaborate with Roche on Therapeutic Delivery Across Blood-Brain Barrier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/21/2014)... CannabisClassifieds.com celebrates marijuana’s new legal place at the table with ... the site has provided its faithful users with everything it ... It uniquely combines the benefits of platforms like Craigslist, Ebay ... masses. Assuring the potent herb’s followers it’s well on ... , Shane Chattin, Owner of Cannabis Classifieds said ...
(Date:12/20/2014)... MissyDress, a distinguished special dress supplier, has just ... has drastically cut prices to all its prom dresses ... 30, 2015. Many of the hottest styles are sold ... dresses, and more. , A spokesman for MissyDress says, ... A-line princess prom dresses or sweetheart chiffon prom dresses, ...
(Date:12/20/2014)... The print component of Healthy Aging ... of approximately 160,000 copies and an estimated readership of ... vast social media strategy and across a network of ... digital version of the campaign, click here . ... the ladies of CTV’s The Social. Lainey Lui, ...
(Date:12/20/2014)... New York, New York (PRWEB) December 20, 2014 ... ) continue to move forward in U.S. ... a new study which suggests that children treated ... prolactin, a hormone linked to breast development and ... Psychopharmacology, looked at 34 children and adolescents who ...
(Date:12/20/2014)... Xarelto bleeding lawsuits filed by men ... and other serious side effects will be consolidated in ... coordinated pretrial proceedings, Wright & Schulte LLC reports. The ... order Friday to transfer 21 Xarelto lawsuits and over ... to the Louisiana district court for coordination by Judge ...
Breaking Medicine News(10 mins):Health News:CannabisClassifieds.com Maintains its “Craigslist for Cannabis” Standing with Website Re-launch 2Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2Health News:The ladies of The Social urge Canadian women to put themselves first over the holiday season and into the new year in Mediaplanet’s “Women’s Health” campaign 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 3Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 4
... June 2 The International Rett Syndrome,Foundation announced ... as Chief Scientific Officer, beginning July 1. Dr. ... network of Rett,Clinics, a series of clinics throughout ... In addition, Dr. Horton will,assist the IRSF Board ...
... FDA has said evidence of drug,s effectiveness lacking , , MONDAY, ... people with Parkinson,s disease combat the tics, spasms and tremors ... study suggests. , Istradfeylline works by helping nerve and ... that leads to Parkinson,s. A study of 395 Parkinson,s patients ...
... for Bad Bugs , A team of Burnham investigators ... to generate chemical inhibitors of human proteins that are hijacked ... provide a new strategy for treating infectious diseases. Because these ... targets, the hope is that resistant forms will not emerge ...
... Center, representatives available at the ASHP 2008 Summer Meeting and ... ... MOUNTAIN VIEW, Calif. and KNOXVILLE, Tenn., June 2, Omnicell, Inc., ... acute healthcare facilities, and the University of,Tennessee Medical Center today ...
... growing ... company in Alberta, CALGARY, June ... leader in the rapidly growing market for,digital radiography, today announced that ... 20th annual PROFIT 100 by PROFIT,Magazine., PROFIT Magazine, which provides ...
... & Science University Cancer Institute researchers have found that a ... the body,s own immune system to fight prostate cancer. The ... a serious type of prostate cancer one where the ... in some cases, also to chemotherapy. , Darryl Pape ...
Cached Medicine News:Health News:The International Rett Syndrome Foundation Names Antony Horton Ph.D. Chief Scientific Officer 2Health News:Drug May Cut Tremors Associated With Parkinson's 2Health News:Recent developments at Burnham Institute 2Health News:University of Tennessee Medical Center Initiates Patient-Specific Medication Management With SinglePointe(TM) Solution From Omnicell 2Health News:University of Tennessee Medical Center Initiates Patient-Specific Medication Management With SinglePointe(TM) Solution From Omnicell 3Health News:IDC ranked no. 6 of Canada's 100 fastest growing companies by PROFIT Magazine 2Health News:IDC ranked no. 6 of Canada's 100 fastest growing companies by PROFIT Magazine 3Health News:OHSU Cancer Institute finds that drug stimulated immune system in prostate cancer 2Health News:OHSU Cancer Institute finds that drug stimulated immune system in prostate cancer 3
(Date:12/19/2014)... 19, 2014  Advanced Medical Isotope Corporation ("AMIC") ... primarily in the development of brachytherapy devices and ... announced that a Life Sciences Discovery Fund (LSDF) ... which AMIC is the commercialization partner.  The award ... the proposal titled "Optimized Injectable Radiogels for High-dose ...
(Date:12/19/2014)... Ill. , Dec. 19, 2014   Hospira, ... leading provider of injectable drugs and infusion technologies, today ... Morgan 33rd Annual Healthcare Conference on Wednesday, Jan. 14, ... presentation is scheduled to begin at 10:30 a.m. Pacific ... available to all interested parties through a live audiocast ...
(Date:12/19/2014)... 19, 2014 In today,s rapidly changing, ... communication tools are essential for survival. The world ... consumers, desires, preferences, and unmet needs are evolving ... groups across all industries are continually searching for ... the adoption of new market research techniques like ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 3Study Uncovers New Tools and Techniques for Understanding Consumer Decision Making 2
... 2012 Pinnacle Biologics is pleased to announce the appointment ... as its exclusive distributor for ETHYOL (amifostine) and PHOTOFRIN ... Ethyol is a cytoprotective agent indicated to reduce the ... radiation treatment for head and neck cancer and to ...
... Mass., April 18, 2012  Researchers in the Program in Cellular ... the Immune Disease Institute (PCMM/IDI) have developed a ... to using RNA-based gene silencing technologies to treat cancer: Making ... there. Judy Lieberman , PhD, of ...
Cached Medicine Technology:Pinnacle Biologics Inc. Announces Appointment of Bioprojet Pharma as Exclusive Distributor in Select European Countries 2Packaging therapeutic RNAs for targeted treatment of breast cancer 2Packaging therapeutic RNAs for targeted treatment of breast cancer 3Packaging therapeutic RNAs for targeted treatment of breast cancer 4
Thesystem combines an exclusive dual light-source design and a versatile sample compartment to provide solid, reliable performance....
Inquire...
The new Gemini EM microplate spectrofluorometer builds on the successful Gemini platform. This next generation reader incorporates all of the high performance features of the Gemini XS with new capab...
The Fluoroskan Ascent FL is equipped with both fluorometric and luminometric measurement technologies, providing a full coverage for fluorometric, glow and flash luminometric applications even in the...
Medicine Products: